Robin Farmanfarmaian

Angel investor in Palo Alto

Invests in AI

Robin Farmanfarmaian's investor profile lists AI alongside Healthcare & Biotech, at seed. The record holds 8 deals, among them CyGene Laboratories, IntelliMedicine and Speak About AI.

Email Investor

Email Investor

Credits to line up before a seed round

Robin Farmanfarmaian backs companies at seed. A few of the larger credit programs on AI Perks for teams at that point:

Portfolio on record

Portfolio companies

  • CyGene Laboratories
  • IntelliMedicine
  • Speak About AI
  • HealthTap
  • San Francisco Opera BRAVO!
  • Ad Valorem Appraisal
  • Reflection.io
  • iSono Health

Investment focus

Backs startups in
Artificial Intelligence, Healthcare & Biotech
Rounds
Seed
Profile
Angel investor
Deals on record
8
Based in
Palo Alto, United States

Ready to pitch AI investors?

AI Perks profiles show public professional information only, so there are no contact details here. Continue to find investors, send your pitch and track the replies.

Email Investor

Email Investor

More AI investors on AI Perks

Browse all AI investors

Questions founders ask

Does Robin Farmanfarmaian invest in AI startups?
Yes. Artificial Intelligence is one of the sectors on Robin Farmanfarmaian's investor profile, together with Healthcare & Biotech. The stages on record are seed.
Which companies has Robin Farmanfarmaian backed?
The record lists 8 deals, including CyGene Laboratories, IntelliMedicine, Speak About AI, HealthTap and San Francisco Opera BRAVO!. None of them has a perk listed on AI Perks yet.
What credits can a startup claim before pitching Robin Farmanfarmaian?
For a company raising a seed round, AI Perks lists credits such as Retool via Hatch (up to $12,000), Weaviate (up to $100,000), Neon (up to $100,000) and Amazon Bedrock (up to $200,000), with each program's terms and how to apply.
Does AI Perks publish investor contact details?
No. AI Perks profiles show public professional information only: name, role, location, stages, sectors and the portfolio on record. To reach investors, continue with the Email Investor button below.Email Investor

Email Investor

Source: public professional information. Is this you? Request removal

Email Investor

Email Investor